Earnings growth is expected to lead to a small-cap recovery, the boutique manager says
[ad_1] A boutique fund manager said the recent underperformance of Australian small caps compared to their larger peers was likely to reverse, positioning the asset class as an attractive opportunity for investors “right now”. In its latest research, Prime Value…
The collapse of US banks fuels the debate about the future of crypto
[ad_1] Bitcoin jumped to its highest level in nine months after initially collapsing following the recent bankruptcy of US banks including Silicon Valley Bank (SVB), Signature Bank and Silvergate Capital. After trading around US$22,000 last week, the cryptocurrency fell below…
Orthocell announces distribution agreement in Singapore
[ad_1] Orthocell (ASX:OCC) has appointed Device Technologies Asia (DT Asia) as the exclusive distributor for its neurorepair device Remplir in Singapore. This will be the product’s first major international expansion beyond Australia and New Zealand, where sales have grown significantly….
Tariffs may not hurt directly, but a slowdown in China could
[ad_1] Martin Conlon, Schroder’s head of Australian equity, said Donald Trump’s tariffs on China posed a risk to Australia, particularly if they weakened the Chinese economy and reduced demand for Australian exports. As well as the direct economic impact, Conlon…
Web Travel announces $150 million share buyback amid mixed half-year results
[ad_1] web travel group (ASX:WEB) reported mixed results for the half year ending September 30, 2024, the first reporting period following the demerger of its B2C business. The split, which was completed on September 30, saw Web Travel retain WebBeds’…
Cooling consumption and higher tariffs to moderate US growth in 2025: Robeco
[ad_1] In its baseline scenario, Robeco expects US growth to slow next year due to cooling consumption and higher tariffs. In its economic outlook for 2025 “This is not a landing”the firm forecasts real GDP growth of 1.7 percent, reflecting…
Novonix prepares to expand with $44.4 million in funding
[ad_1] novonix (ASX:NVX) has completed a full institutional underwriting of $44.4 million and issued approximately 74.1 million new shares at a price of $0.60 per share. The offering was targeted at institutional and sophisticated investors, had strong support from existing…
Superhero is expanding into New Zealand
[ad_1] Announcing the move on Tuesday, Superhero said New Zealand investors could now trade Australian and US-listed shares on the platform, while the ability to trade New Zealand shares was on the way. Superhero CEO and co-founder, John Winters, said:…
Have the markets underestimated the geopolitical risks amid the escalation in Ukraine?
[ad_1] Despite significant developments — such as Ukraine’s use of US-supplied missiles on Russian territory and Moscow’s alarming nuclear rhetoric — investors have shown limited reaction, raising concerns among some that longer-term risks are being underestimated. Nigel Green, chief executive…
PYC Therapeutics advances kidney disease drug to human clinical trials
[ad_1] PYC Therapeutics (ASX:PYC) announced plans to advance its investigational drug candidate, PYC-003, into human clinical trials for autosomal dominant polycystic kidney disease (PKD) in early 2025. This decision follows the completion of preclinical studies demonstrating safety, efficacy, and targeted…